Novo Nordisk A/S (NVO)
41.65
+1.00
(+2.46%)
USD |
NYSE |
Nov 13, 16:00
41.49
-0.16
(-0.38%)
After-Hours: 19:59
Novo Nordisk Shareholders Equity (Quarterly) : 33.09B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 33.09B |
| June 30, 2026 | 33.84B |
| March 31, 2026 | 31.31B |
| December 31, 2025 | 30.51B |
| September 30, 2025 | 26.74B |
| June 30, 2025 | 26.44B |
| March 31, 2025 | 20.06B |
| December 31, 2024 | 19.92B |
| September 30, 2024 | 18.04B |
| June 30, 2024 | 16.17B |
| March 31, 2024 | 14.32B |
| December 31, 2023 | 15.79B |
| September 30, 2023 | 13.20B |
| June 30, 2023 | 13.26B |
| March 31, 2023 | 11.65B |
| December 31, 2022 | 11.98B |
| September 30, 2022 | 10.10B |
| June 30, 2022 | 10.47B |
| March 31, 2022 | 9.955B |
| December 31, 2021 | 10.82B |
| September 30, 2021 | 10.30B |
| June 30, 2021 | 10.46B |
| March 31, 2021 | 9.244B |
| December 31, 2020 | 10.41B |
| September 30, 2020 | 9.385B |
| Date | Value |
|---|---|
| June 30, 2020 | 9.050B |
| March 31, 2020 | 7.999B |
| December 31, 2019 | 8.651B |
| September 30, 2019 | 7.732B |
| June 30, 2019 | 8.100B |
| March 31, 2019 | 7.117B |
| December 31, 2018 | 7.941B |
| September 30, 2018 | 7.400B |
| June 30, 2018 | 7.691B |
| March 31, 2018 | 7.299B |
| December 31, 2017 | 8.034B |
| September 30, 2017 | 7.458B |
| June 30, 2017 | 7.430B |
| March 31, 2017 | 5.796B |
| December 31, 2016 | 6.422B |
| September 30, 2016 | 6.237B |
| June 30, 2016 | 6.359B |
| March 31, 2016 | 5.703B |
| December 31, 2015 | 6.837B |
| September 30, 2015 | 6.450B |
| June 30, 2015 | 5.842B |
| March 31, 2015 | 4.616B |
| December 31, 2014 | 6.548B |
| September 30, 2014 | 6.443B |
| June 30, 2014 | 6.733B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| AstraZeneca PLC | 47.33B |
| GSK Plc | 24.91B |
| Johnson & Johnson | 81.53B |
| Eli Lilly & Co. | 40.27B |
| Merck & Co., Inc. | 44.89B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 91.04B |
| Total Liabilities (Quarterly) | 57.94B |
| Debt to Equity Ratio | 0.6174 |
| Current Ratio | 0.8449 |
| Net Debt Paydown Yield | -0.76% |